Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19
| Autor: | Margherita Gaudenzi, Riccardo M. Inciardi, Filippo M. Sarullo, Michele Senni, Matteo Pagnesi, Carlo Lombardi, Marco Metra, Antonio Bellasi, Francesco Catagnano, Gianfranco Sinagra, Laura Adelaide Dalla Vecchia, Massimiliano Gnecchi, Lucia Barbieri, Daniela Tomasoni, Annamaria Iorio, Gregorio Zaccone, Marco Guazzi, Stefano Giovinazzo, Davide Margonato, Andrea Mortara, Maurizio Volterrani, Mattia Di Pasquale, Massimo F Piepoli, Stefano Carugo, Maria Teresa La Rovere, Marco Merlo, Vincenzo Nuzzi, Andrea Pozzi, Valentina Carubelli, Sergio Leonardi, Piergiuseppe Agostoni, Italo Porto, Rita Camporotondo, Gloria Maccagni, Massimo Mapelli, Luca Monzo, Claudia Canale, Pietro Ameri, Gian Battista Danzi, Chiara Tedino |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology Infectious and parasitic diseases RC109-216 Lower risk 03 medical and health sciences 0302 clinical medicine Glucocorticoid Fraction of inspired oxygen Internal medicine medicine Clinical endpoint Corticosteroid 030212 general & internal medicine Adverse effect Steroid biology business.industry SARS-CoV-2 C-reactive protein COVID-19 Retrospective cohort study General Medicine Infectious Diseases Coronary care unit biology.protein business medicine.drug |
| Zdroj: | International Journal of Infectious Diseases, Vol 108, Iss, Pp 270-273 (2021) |
| ISSN: | 1201-9712 |
| Popis: | Background: Glucocorticoid therapy has emerged as an effective therapeutic option in hospitalized patients with coronavirus disease 2019 (COVID-19). This study aimed to focus on the impact of relevant clinical and laboratory factors on the protective effect of glucocorticoids on mortality. Methods: A sub-analysis was performed of the multicenter Cardio-COVID-Italy registry, enrolling consecutive patients with COVID-19 admitted to 13 Italian cardiology units between 01 March 2020 and 09 April 2020. The primary endpoint was in-hospital mortality. Results: A total of 706 COVID-19 patients were included (349 treated with glucocorticoids, 357 not treated with glucocorticoids). After adjustment for relevant covariates, use of glucocorticoids was associated with a lower risk of in-hospital mortality (adjusted HR 0.44; 95% CI 0.26–0.72; p = 0.001). A significant interaction was observed between the protective effect of glucocorticoids on mortality and PaO2/FiO2 ratio on admission (p = 0.042), oxygen saturation on admission (p = 0.017), and peak CRP (0.023). Such protective effects of glucocorticoids were mainly observed in patients with lower PaO2/FiO2 ratio (100 mg/L). Conclusions: The protective effects of glucocorticoids on mortality in COVID-19 were more evident among patients with worse respiratory parameters and higher systemic inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|